Biological Effects of Hydrogen Water on Subjects with NAFLD: A Randomized, Placebo-Controlled Trial.
Branislav Kura, Maria Szantova, Tyler W LeBaron, Viliam Mojto, Miroslav Barancik, Barbara Szeiffova Bacova, Barbora Kalocayova, Matus Sykora, Ludmila Okruhlicova, Narcisa Tribulova, Anna Gvozdjakova, Zuzana Sumbalova, Jarmila Kucharska, Xenia Faktorova, Martina Jakabovicova, Zuzana Durkovicová, Jan Macutek, Michaela Koscová, Jan Slezak · Antioxidants (Basel, Switzerland) · 2022
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 30 participants with NAFLD, HRW was well-tolerated, with no significant changes in liver enzymes and a trend of improved lipid profile and reduced lactate dehydrogenase levels.
What the Researchers Studied
30 participants with NAFLD.
How the Study Was Conducted
Randomized, double-blind, placebo-controlled human clinical trial.
How Molecular Hydrogen Was Used
The researchers administered hydrogen-rich water (HRW) to 30 subjects with NAFLD in a randomized, double-blinded, placebo-controlled manner for eight weeks.
What the Researchers Found
HRW was well-tolerated, with no significant changes in liver enzymes and a trend of improved lipid profile and reduced lactate dehydrogenase levels.
Authors’ Conclusion
The authors concluded that the favorable trends in this study in conjunction with previous animal and clinical findings suggest that HRW may serve as an important adjuvant therapy for promoting and maintaining optimal health and wellness.